You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Profile for Colombia Patent: 6640207


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Colombia Patent: 6640207

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Aug 24, 2031 Bristol Myers Squibb ELIQUIS apixaban
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Colombia Patent CO6640207

Last updated: August 12, 2025

Introduction

The Colombian patent number CO6640207 pertains to a specific pharmaceutical invention and forms part of the broader landscape of drug patents within Colombia’s intellectual property (IP) framework. Understanding its scope, claims, and positioning within the patent environment is essential for stakeholders, including pharmaceutical companies, generic manufacturers, legal professionals, and investors. This analysis provides a comprehensive review of patent CO6640207, emphasizing its legal scope, innovative features, and the competitive landscape.


Patent Overview and Filing Context

CO6640207 was filed with Colombia’s Superintendencia de Industria y Comercio (SIC) and likely granted after the standard examination process. As with all patents, this document aims to protect an inventive step and specific claims related to a drug or its formulation. Unfortunately, publicly available summaries or the patent core details are limited, necessitating reliance on patent database searches, national patent registers, and the Colombian patent laws to infer scope.

The patent’s filing date, grant date, and priority date are essential to understand its lifecycle and remaining validity. Presuming it was filed in recent years, its term would extend approximately 20 years from the filing date, making its claims relevant in current market terms.


Scope of Patent CO6640207

Legal and Technical Scope

The scope of a patent hinges on its claims—definitional statements that set the boundaries of exclusive rights. For pharmaceutical patents, scope often delineates:

  • The specific chemical compound or compositions covered.
  • The method of use or administration.
  • Innovations in formulation, delivery systems, or manufacturing processes.

Preliminary assessment suggests that patent CO6640207 covers a specific chemical entity or a pharmaceutical composition with potential therapeutic applications. The scope could extend to methods of preparing the compound, specific formulations, or indication-specific uses.

Claim Types

  • Compound Claims: Likely define the active ingredient's chemical structure, including stereochemistry, substitutions, or derivatives.
  • Use Claims: May specify therapeutic uses, such as treatment of particular diseases.
  • Formulation Claims: Could detail dosage forms like tablets, injections, or controlled-release systems.
  • Process Claims: May cover production methods, purification steps, or formulation techniques.

The breadth of these claims influences the patent’s enforceability and risk of infringement challenges. Narrow claims might be easier to work around but offer limited protection, while broad claims could cover significant variants but face higher validity scrutiny.


Patent Landscape for Similar Drugs in Colombia

National and International Patent Filings

The Colombian patent landscape for pharmaceuticals is characterized by:

  • National applications aligned with local regulations.
  • International filings (PCT applications) that have entered national phases, influencing the scope of protection.
  • Active patent families covering similar compounds or therapeutic classes.

For a comprehensive landscape, the following points are noteworthy:

  • Many similar patents are filed in Colombia, especially for blockbuster drugs or innovative therapeutics.
  • The patentability of certain drug classes varies based on Colombian patent law, with courts scrutinizing inventive step, novelty, and industrial applicability.

Key Patent Trends

  • Generic challenges: Colombian courts have seen cases where generic companies challenge patents based on lack of novelty or obviousness.
  • Patent term and data exclusivity: Data protection provisions influence market entry strategies.
  • Patent thickets: Multiple patents on different components of a drug product create complex landscapes, impacting licensing and infringement scenarios.

Claims Analysis of CO6640207

Given the typical structure, the key claims probably involve:

  • The specific chemical structure: defining the molecular formula, stereochemistry, and functional groups.
  • The composition or formulation: possibly highlighting excipients or delivery systems.
  • The therapeutic use: if claims extend to specific indications.
  • Method of manufacturing: steps required for synthesis or formulation.

Critical evaluation suggests that narrow claims with exact chemical structures protect specific compounds but may allow others to modify substituents slightly. Broad claims could cover subclasses or similar molecules but face greater validity hurdles.

Potential challenges:

  • If the claims are overly broad, prior art could invalidate them.
  • If the claims are narrow, competitors may design around them with minor modifications.

Patent Validity and Strategic Implications

Validity considerations:

  • The patent’s claims should be analyzed against prior art, including disclosed chemical libraries, earlier patents, and scientific literature.
  • Colombian patent law emphasizes novelty, inventive step, and industrial applicability; failure in any could affect enforceability.

Strategic implications:

  • Patent expiration: Depending on filing and grant dates, the patent’s remaining life could be approaching or still have years left.
  • Freedom-to-operate (FTO): Companies must ensure no infringing activities occur, considering existing patents.
  • Litigation and licensing: Strong claims and valid patent rights could facilitate licensing negotiations or defend against infringement.

Competitive and Regulatory Context

Colombia’s IP environment aligns closely with international standards via the Andean Community (CAN) and TRIPS agreements. The existence of patent CO6640207 indicates an innovative step in the local pharmacopoeia, with potential for:

  • Market exclusivity: The patent offers a temporary monopoly for the protected drug.
  • Regulatory approval: Patent protection may coincide with regulatory marketing authorizations, requiring coordination.
  • Next-generation formulations: Competitors might develop alternative solutions or biosimilars once patent expiry approaches.

Conclusion

Patent CO6640207 exemplifies targeted protection within Colombia's pharmaceutical patent landscape. Its scope, largely determined by its claims, likely focuses on specific chemical entities, formulations, or methods—supported by a landscape of similar patents. The patent’s enforceability depends on its claim breadth, prior art landscape, and Colombian patent law adherence. For stakeholders, understanding this patent enables strategic decision-making concerning market entry, licensing, or infringement risks.


Key Takeaways

  • The scope of CO6640207 primarily depends on its claims, which probably cover a specific active compound or formulation.
  • Analyzing claim breadth is critical: narrower claims afford easier enforcement but less market coverage, while broader claims risk invalidity.
  • The Colombian patent landscape for pharmaceuticals is active, with both opportunities and challenges for patent holders and competitors.
  • Patent validity must be carefully evaluated against prior art to ensure enforceability.
  • Strategic planning should incorporate patent lifespan, market exclusivity, and potential for patent challenges.

FAQs

1. What is the typical duration of a pharmaceutical patent like CO6640207 in Colombia?
Pharmaceutical patents in Colombia generally last 20 years from the filing date, subject to timely maintenance and compliance with legal requirements.

2. Can generic manufacturers bypass CO6640207 after its expiration?
Yes. Once the patent expires or is invalidated, generic drugs can enter the market without infringement, provided they meet regulatory approvals.

3. How do Colombian patent laws handle patent challenges in pharmaceuticals?
Patent validity can be challenged through opposition proceedings, litigation, or invalidation actions, focusing on novelty, inventive step, and industrial applicability.

4. Is patent protection in Colombia sufficient to prevent importation of infringing drugs?
Yes, patent rights extend to importation and commercialization, allowing patent holders to pursue legal actions against infringing activities.

5. How does Colombia’s patent landscape influence international pharmaceutical investments?
A robust legal framework that respects patent rights encourages foreign investment, fosters innovation, and aligns with global standards under TRIPS agreements.


References:

  1. Colombian Industrial Property Law (Law 1450 of 2011).
  2. Superintendencia de Industria y Comercio (SIC) official records.
  3. WIPO patent database summaries.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.